OBI Pharma和TegMine治疗项目伙伴利用ADC技术开发新的癌症治疗。 OBI Pharma and TegMine Therapeutics partner to develop new cancer treatments using ADC technology.

OBI Pharma是一家肿瘤学公司,它与TegMine治疗公司合作开发新的抗体-药物共治癌症疗法。 OBI Pharma, an oncology company, has partnered with TegMine Therapeutics to develop new antibody-drug conjugate (ADC) cancer treatments. 根据他们的协议,TegMine将使用OBI的GlycobI ADC技术来确定潜在的新的治疗方法。 Under their agreement, TegMine will use OBI’s GlycOBI® ADC technology to identify potential new therapeutics. 如果成功,这些公司将签订正式的许可证协议,以进一步为医疗需求未得到满足的患者开发这些ADC候选人。 If successful, the companies will enter a formal licensing agreement to further develop these ADC candidates for patients with unmet medical needs.